Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trialMarc Cohen, Kenneth W. Mahaffey, Glenn N. Levine et al.|Catheterization and Cardiovascular Interventions|2009Cited by 19
Role of UVA-driven cellular senescence via mTOR activation in dihydrotestosterone-induced hair loss in androgenetic alopecia mouse modelDongfan Wei, Xiuzu Song, Li Zhang et al.|Journal of Photochemistry and Photobiology B Biology|2025Cited by 5